All In Biotech

Drug Trial Radar · NCT04541108

Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies

A Phase 0 Master Protocol Using the CIVO® Platform to Evaluate Intratumoral Microdoses of Anti-Cancer Therapies in Patients With Solid Tumors

Last checked: Nov 19, 2026Latest source record: May 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

15

Planned (sponsor's estimate)

Start

Jul 26, 2021

Primary completion

Dec 2031

Study completion Dec 2031

Sponsor

Lead sponsor
Presage BiosciencesIndustry
Sponsor type
Industry
First posted
Sep 9, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Early phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multi-center, open-label Phase 0 Master Protocol designed to study the localized pharmacodynamics (PD) of anti-cancer therapies within the tumor microenvironment (TME) when administered intratumorally in microdose quantities via the CIVO device in patients with surface accessible solid tumors for which there is a scheduled surgical intervention. CIVO stands for Comparative In Vivo Oncology. Multiple substudies will include specified investigational agents and combinations to be evaluated.

Conditions

  • Solid Tumor

Interventions

  • RilvegostomigBiological

    Intratumoral microdose injection by the CIVO device.

  • VolrustomigBiological

    Intratumoral microdose injection by the CIVO device.

  • SabestomigBiological

    Intratumoral microdose injection by the CIVO device.

  • PembrolizumabBiological

    Intratumoral microdose injection by the CIVO device.

  • AZD9592Biological

    Intratumoral microdose injection by the CIVO device

  • AZD9592 + RilvegostomigCombination product

    Intratumoral microdose injection by the CIVO device

  • AZD9592 + VolrustomigCombination product

    Intratumoral microdose injection by the CIVO device

  • AZD9592 + SabestomigCombination product

    Intratumoral microdose injection by the CIVO device

  • AZD9592 + PembrolizumabCombination product

    Intratumoral microdose injection by the CIVO device

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Quantification of Selected Pharmacodynamic Biomarkers as Specified in Substudies by IHC, ISH, and/or Spatial Biology PlatformsTime frame: 4 hours-7 days after microdose injection

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • LSU Health Sciences Center - Shreveport

    Shreveport, Louisiana

  • Montefiore Medical Center

    The Bronx, New York

  • University of North Carolina

    Chapel Hill, North Carolina

  • UC Health

    Cincinnati, Ohio

  • Oregon Health & Science University (OHSU)

    Portland, Oregon

  • University of Pennsylvania

    Philadelphia, Pennsylvania

  • Sarah Cannon Research Institute

    Charleston, South Carolina

  • MUSC Hollings Cancer Center

    Charleston, South Carolina

  • University of Washington

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.